639 related articles for article (PubMed ID: 31099633)
1. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
Pennell NA; Arcila ME; Gandara DR; West H
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():531-542. PubMed ID: 31099633
[TBL] [Abstract][Full Text] [Related]
2. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman J; Chirieac LR; D'Amico TA; DeCamp MM; Dilling TJ; Dobelbower M; Doebele RC; Govindan R; Gubens MA; Hennon M; Horn L; Komaki R; Lackner RP; Lanuti M; Leal TA; Leisch LJ; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2017 Apr; 15(4):504-535. PubMed ID: 28404761
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
Song Y; Zhou Q; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Yao LD; Zhan LJ; Yang F; Wu YL
Lung Cancer; 2018 Sep; 123():7-13. PubMed ID: 30089597
[TBL] [Abstract][Full Text] [Related]
5. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.
García-Campelo R; Bernabé R; Cobo M; Corral J; Coves J; Dómine M; Nadal E; Rodriguez-Abreu D; Viñolas N; Massuti B
Clin Transl Oncol; 2015 Dec; 17(12):1020-9. PubMed ID: 26691657
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer.
Ettinger DS; Akerley W; Borghaei H; Chang AC; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Ganti AK; Govindan R; Grannis FW; Horn L; Jahan TM; Jahanzeb M; Kessinger A; Komaki R; Kong FM; Kris MG; Krug LM; Lennes IT; Loo BW; Martins R; O'Malley J; Osarogiagbon RU; Otterson GA; Patel JD; Pinder-Schenck MC; Pisters KM; Reckamp K; Riely GJ; Rohren E; Swanson SJ; Wood DE; Yang SC; Hughes M; Gregory KM;
J Natl Compr Canc Netw; 2012 Oct; 10(10):1236-71. PubMed ID: 23054877
[TBL] [Abstract][Full Text] [Related]
7. Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.
Swalduz A; Souquet PJ; Pérol M; Moro-Sibilot D; Schiffler C; Chabaud S; Fayet Y; Rogasik M; Labrosse H; Farsi F; Brun P; Decroisette C; Bombaron P; Bringuier PP; Haddad V; Forest F; Peoc'h M; Lantuejoul S; de Fraipont F; Ray-Coquard I; Fournel P
Future Oncol; 2019 Jun; 15(18):2139-2149. PubMed ID: 31185741
[No Abstract] [Full Text] [Related]
8. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
Khozin S; Miksad RA; Adami J; Boyd M; Brown NR; Gossai A; Kaganman I; Kuk D; Rockland JM; Pazdur R; Torres AZ; Zhi J; Abernethy AP
Cancer; 2019 Nov; 125(22):4019-4032. PubMed ID: 31381142
[TBL] [Abstract][Full Text] [Related]
9. Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Rajadurai P; Cheah PL; How SH; Liam CK; Annuar MAA; Omar N; Othman N; Marzuki NM; Pang YK; Bustamam RSA; Tho LM
Lung Cancer; 2019 Oct; 136():65-73. PubMed ID: 31446227
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Friedlaender A; Banna G; Patel S; Addeo A
Curr Treat Options Oncol; 2019 Sep; 20(10):79. PubMed ID: 31482479
[TBL] [Abstract][Full Text] [Related]
11. Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.
Heigener DF; Kerr KM; Laing GM; Mok TSK; Moiseyenko FV; Reck M
Clin Cancer Res; 2019 Aug; 25(16):4881-4887. PubMed ID: 30910855
[TBL] [Abstract][Full Text] [Related]
12. Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.
Fox AH; Nishino M; Osarogiagbon RU; Rivera MP; Rosenthal LS; Smith RA; Farjah F; Sholl LM; Silvestri GA; Johnson BE
CA Cancer J Clin; 2023; 73(4):358-375. PubMed ID: 36859638
[TBL] [Abstract][Full Text] [Related]
13. Non-Small Cell Lung Cancer, Version 4.2024.
Riely GJ; Wood DE; Ettinger DS; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Desai AP; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Juloori A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Mullikin TC; Ng T; Owen D; Owen DH; Patel SP; Patil T; Polanco PM; Riess J; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hang L
J Natl Compr Canc Netw; 2024 May; 22(4):249-274. PubMed ID: 38754467
[TBL] [Abstract][Full Text] [Related]
14. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
Mileham KF; Schenkel C; Bruinooge SS; Freeman-Daily J; Basu Roy U; Moore A; Smith RA; Garrett-Mayer E; Rosenthal L; Garon EB; Johnson BE; Osarogiagbon RU; Jalal S; Virani S; Weber Redman M; Silvestri GA
Cancer Med; 2022 Jan; 11(2):530-538. PubMed ID: 34921524
[TBL] [Abstract][Full Text] [Related]
15. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
16. Abandoning the Notion of Non-Small Cell Lung Cancer.
Relli V; Trerotola M; Guerra E; Alberti S
Trends Mol Med; 2019 Jul; 25(7):585-594. PubMed ID: 31155338
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns in non-small-cell lung cancer in USA: results of the CancerMPact Survey 2018.
Robinson D; Hawthorne S; Zhao L; Hanson M; Kanas G; Davis C; Clark O
Future Oncol; 2020 Mar; 16(7):255-262. PubMed ID: 32019323
[No Abstract] [Full Text] [Related]
19. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
[TBL] [Abstract][Full Text] [Related]
20. Updates in non-small cell lung cancer.
Walker S
Clin J Oncol Nurs; 2008 Aug; 12(4):587-96. PubMed ID: 18676326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
